Considering that the phosphatase activity of CD45 is critical for multiple leukocyte functions, pan-CD45 phosphatase inhibitors will probably not be applicable for CRC therapy because of adverse effects. The gene discussed is PTPRC; the disease is colorectal carcinoma.